Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Elevance Health Inc.

There’s a lot to be optimistic about in the Industrial Goods sector as 3 analysts just weighed in on Spire Global (SPIR – Research Report), Grupo A...

Analysts Offer Insights on Industrial Goods Companies: Spire Global (SPIR), Grupo Aeroportuario del Sureste (ASR) and Electrovaya (ELVA)

Electrovaya ( ($TSE:ELVA) ) has issued an update. Electrovaya Inc. announced significant business updates, including insider share purchases and pr...

Electrovaya Advances with Strategic Investments and Gigafactory Progress

Electrovaya ( ($TSE:ELVA) ) just unveiled an announcement. Electrovaya Inc. announced its participation in three upcoming investor conferences, hig...

Electrovaya to Engage Investors at Key Conferences

Shares of top health insurers, including Oscar Health ($OSCR), Elevance Health ($ELV), and Centene ($CNC), fell on Monday. The recent decline follo...

OSCR, ELV, CNC: Why Investors Are Selling Health-Insurance Stocks

Electrovaya ( ($TSE:ELVA) ) just unveiled an announcement. Electrovaya Inc. has successfully closed an oversubscribed public offering, raising appr...

Electrovaya Closes Oversubscribed $28.1 Million Public Offering

Elevra Lithium ( ($AU:ELV) ) has provided an announcement. Elevra Lithium Limited has announced the quotation of 582,770 fully paid ordinary securi...

Elevra Lithium Expands Market Presence with New ASX Quotation

Elevra Lithium ( ($AU:ELV) ) has issued an update. Elevra Lithium Limited has issued 287,500 new fully paid ordinary shares at $4.80 per share to C...

Elevra Lithium Settles Underwriting Fees with Share Issuance

An announcement from Elevra Lithium ( ($AU:ELV) ) is now available. Elevra Lithium has completed a significant merger with Sayona Mining Limited an...

Elevra Lithium Strengthens Position with Strategic Merger and Expansion Plans

Enliven Therapeutics, Inc. (($ELVN)) announced an update on their ongoing clinical study. Enliven Therapeutics, Inc. is conducting a Phase 1 clinic...

Enliven Therapeutics’ ELVN-001: A Promising Phase 1 Study for Chronic Myeloid Leukemia

In a report released on October 22, Ben Hendrix from RBC Capital maintained a Buy rating on Elevance Health, with a price target of $392.00. The co...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELV	$321.73	+2.47%	1.17M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELV	$321.73	+2.5%	1.17M
3
4
5
6

ELV

ELV

Get Elevance Health Inc. Data in Excel

Get Elevance Health Inc. Data in Excel